LIM kinases, promising but reluctant therapeutic targets: chemistry and preclinical validation in vivo

Rayan Berabez (1) , Sylvain Routier (1) , Hélène Bénédetti (2) , Karen Plé (1) , Béatrice Vallée (2)

1 ICOA - Institut de Chimie Organique et Analytique
2 CBM - Centre de biophysique moléculaire

LIM Kinases are important actors in the regulation of cytoskeleton dynamics by controlling microtubule and actin filament turnover. The signaling pathways involving LIM kinases for actin filament remodeling are well established. They are downstream effectors of small G proteins of the Rho-GTPases family and have become promising targets for the treatment of several major diseases because of their position at the lower end of these signaling cascades. Cofilin, which depolymerizes actin filaments, is the best-known substrate of these enzymes. The phosphorylation of cofilin to its inactive form by LIM kinases avoids actin filament depolymerization. The balance between phosphorylated and non-phosphorylated cofilin is thought to play an important role in tumor cell invasion and metastasis. Since 2006, many small molecules have been developed for LIMK inhibition, and in this review article, we will discuss the structure–activity relationships of the few inhibitor families that have been tested in vivo on different pathological models.

Mots clés: LIMK; medicinal chemistry; in vivo preclinical validation

Domaines: Chimie; Sciences du Vivant [q-bio]

Rayan Berabez, Sylvain Routier, Hélène Bénédetti, Karen Plé, Béatrice Vallée. LIM kinases, promising but reluctant therapeutic targets: chemistry and preclinical validation in vivo. Cells, 2022, 11 (13), pp.2090. ⟨10.3390/cells11132090⟩. ⟨hal-03721458⟩